These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

114 related articles for article (PubMed ID: 12070862)

  • 1. [Long-term interferon therapy. Effectiveness in multiple sclerosis continues].
    MMW Fortschr Med; 2002 May; Suppl 2():84. PubMed ID: 12070862
    [No Abstract]   [Full Text] [Related]  

  • 2. Immortal time bias in the study of effectiveness of interferon-beta in multiple sclerosis.
    Renoux C; Suissa S
    Ann Neurol; 2008 Jul; 64(1):109-10; author reply 110. PubMed ID: 18668635
    [No Abstract]   [Full Text] [Related]  

  • 3. Are magnetic resonance findings predictive of clinical outcome in therapeutic trials in multiple sclerosis? The dilemma of interferon-beta.
    McDonald WI; Miller DH; Thompson AJ
    Ann Neurol; 1994 Jul; 36(1):14-8. PubMed ID: 8024255
    [No Abstract]   [Full Text] [Related]  

  • 4. [Beta interferon and multiple sclerosis].
    Kinnunen E
    Duodecim; 1996; 112(24):2368-73. PubMed ID: 10605237
    [No Abstract]   [Full Text] [Related]  

  • 5. [Interferon in multiple sclerosis. The earlier, the better?].
    MMW Fortschr Med; 2001 May; 143 Suppl 2():94. PubMed ID: 11434275
    [No Abstract]   [Full Text] [Related]  

  • 6. Interferon-beta1b in multiple sclerosis.
    Buttmann M; Rieckmann P
    Expert Rev Neurother; 2007 Mar; 7(3):227-39. PubMed ID: 17341170
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Interferon-beta1a treatment for multiple sclerosis.
    Sandberg-Wollheim M
    Expert Rev Neurother; 2005 Jan; 5(1):25-34. PubMed ID: 15853471
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Natalizumab: new drug. Multiple sclerosis: risky market approval.
    Prescrire Int; 2008 Feb; 17(93):7-10. PubMed ID: 18354844
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [10 years of interferon treatment in multiple sclerosis. Does the future belong to high-dose therapy?].
    MMW Fortschr Med; 2003 May; 145 Suppl 2():108. PubMed ID: 14579501
    [No Abstract]   [Full Text] [Related]  

  • 10. What can be learned from open direct comparative trials in multiple sclerosis?
    Khan O
    J Neurol Sci; 2009 Feb; 277 Suppl 1():S25-8. PubMed ID: 19200861
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Once weekly interferon beta for multiple sclerosis is superseded by higher and more frequent dosing.
    Blumhardt LD
    Int J Clin Pract Suppl; 2002 Sep; (131):9-16. PubMed ID: 12564807
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Ensuring the long-term effectiveness of MS treatment].
    Krankenpfl J; 2005; 43(7-10):235. PubMed ID: 16515305
    [No Abstract]   [Full Text] [Related]  

  • 13. Full results of the Evidence of Interferon Dose-Response-European North American Comparative Efficacy (EVIDENCE) study: a multicenter, randomized, assessor-blinded comparison of low-dose weekly versus high-dose, high-frequency interferon beta-1a for relapsing multiple sclerosis.
    Schwid SR; Panitch HS
    Clin Ther; 2007 Sep; 29(9):2031-48. PubMed ID: 18035202
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Multiple sclerosis: interferon beta for some serious forms.
    Prescrire Int; 2007 Dec; 16(92):252-7. PubMed ID: 18092425
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Use of interferon-beta in the treatment of multiple sclerosis.
    Derwenskus J; Lublin FD
    Adv Neurol; 2006; 98():257-71. PubMed ID: 16400838
    [No Abstract]   [Full Text] [Related]  

  • 16. Pregnancy outcomes in multiple sclerosis following subcutaneous interferon beta-1a therapy.
    Sandberg-Wollheim M; Alteri E; Moraga MS; Kornmann G
    Mult Scler; 2011 Apr; 17(4):423-30. PubMed ID: 21220368
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Interferon beta and multiple sclerosis: look at the evidence.
    Patti F; Reggio A
    Int J Clin Pract Suppl; 2002 Sep; (131):23-32. PubMed ID: 12564809
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Combination therapy with interferon-beta and glatiramer acetate in multiple sclerosis.
    Ytterberg C; Johansson S; Andersson M; Olsson D; Link H; Holmqvist LW; von Koch L
    Acta Neurol Scand; 2007 Aug; 116(2):96-9. PubMed ID: 17661794
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Interferon-beta therapy for MS: the dilemma of having choices.
    Khan O
    J Neurol Sci; 2004 Jul; 222(1-2):1. PubMed ID: 15240187
    [No Abstract]   [Full Text] [Related]  

  • 20. Calcified subcutaneous nodules: a long-term complication of interferon beta-1a therapy.
    Macbeth AE; Kendall BR; Smith A; Saldanha G; Harman KE
    Br J Dermatol; 2007 Sep; 157(3):624-5. PubMed ID: 17596164
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 6.